Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy.
Lee L, Lim WC, Galas-Filipowicz D, Fung K, Taylor J, Patel D, Akbar Z, Alvarez Mediavilla E, Wawrzyniecka P, Shome D, Reijmers RM, Gregg T, Wood L, Day W, Cerec V, Ferrari M, Thomas S, Cordoba S, Onuoha S, Khokhar N, Peddareddigari V, Al-Hajj M, Cavet J, Zweegman S, Rodriguez-Justo M, Youg K, Pule M, Popat R. Lee L, et al. Among authors: zweegman s. J Immunother Cancer. 2023 Jun;11(6):e006699. doi: 10.1136/jitc-2023-006699. J Immunother Cancer. 2023. PMID: 37399355 Free PMC article.
T-cell-engaging bispecific antibodies in cancer.
van de Donk NWCJ, Zweegman S. van de Donk NWCJ, et al. Among authors: zweegman s. Lancet. 2023 Jul 8;402(10396):142-158. doi: 10.1016/S0140-6736(23)00521-4. Epub 2023 Jun 1. Lancet. 2023. PMID: 37271153 Review.
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.
Lameris R, Ruben JM, Iglesias-Guimarais V, de Jong M, Veth M, van de Bovenkamp FS, de Weerdt I, Kater AP, Zweegman S, Horbach S, Riedl T, Winograd B, Roovers RC, Adang AEP, de Gruijl TD, Parren PWHI, van der Vliet HJ. Lameris R, et al. Among authors: zweegman s. Cell Rep Med. 2023 Mar 21;4(3):100961. doi: 10.1016/j.xcrm.2023.100961. Epub 2023 Mar 2. Cell Rep Med. 2023. PMID: 36868236 Free PMC article.
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.
Hofsink Q, Haggenburg S, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, van Meerloo J, Burger JA, Bouhuijs JH, Smits GP, Wouters D, van Leeuwen EMM, Bontkes HJ, Kootstra NA, Vogels-Nooijen S, Rots N, van Beek J, Heemskerk MHM, Groen K, van Meerten T, Mutsaers PGNJ, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS; COBRA KAI study team. Hofsink Q, et al. EClinicalMedicine. 2023 Jul;61:102040. doi: 10.1016/j.eclinm.2023.102040. Epub 2023 Jun 15. EClinicalMedicine. 2023. PMID: 37337616 Free PMC article.
T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma.
Verkleij CPM, O'Neill CA, Broekmans MEC, Frerichs KA, Bruins WSC, Duetz C, Kruyswijk S, Baglio SR, Skerget S, Montes de Oca R, Zweegman S, Verona RI, Mutis T, van de Donk NWCJ. Verkleij CPM, et al. Among authors: zweegman s. Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-3333. Online ahead of print. Clin Cancer Res. 2024. PMID: 38687588
Monoclonal Antibodies in the Treatment of Multiple Myeloma.
van de Donk NWCJ, Zweegman S. van de Donk NWCJ, et al. Among authors: zweegman s. Hematol Oncol Clin North Am. 2024 Apr;38(2):337-360. doi: 10.1016/j.hoc.2023.12.002. Epub 2023 Dec 26. Hematol Oncol Clin North Am. 2024. PMID: 38151402 Review.
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Mai EK, Hielscher T, Bertsch U, Salwender HJ, Zweegman S, Raab MS, Munder M, Pantani L, Mancuso K, Brossart P, Beksac M, Blau IW, Dürig J, Besemer B, Fenk R, Reimer P, van der Holt B, Hänel M, von Metzler I, Graeven U, Müller-Tidow C, Boccadoro M, Scheid C, Dimopoulos MA, Hillengass J, Weisel KC, Cavo M, Sonneveld P, Goldschmidt H. Mai EK, et al. Among authors: zweegman s. Leukemia. 2024 Mar;38(3):640-647. doi: 10.1038/s41375-023-02105-6. Epub 2023 Dec 7. Leukemia. 2024. PMID: 38062124 Free PMC article. Clinical Trial.
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Frerichs KA, Verkleij CPM, Mateos MV, Martin TG, Rodriguez C, Nooka A, Banerjee A, Chastain K, Perales-Puchalt A, Stephenson T, Uhlar C, Kobos R, van der Holt B, Kruyswijk S, Kuipers MT, Groen K, Vishwamitra D, Skerget S, Cortes-Selva D, Doyle M, Zaaijer HL, Zweegman S, Verona RI, van de Donk NWCJ. Frerichs KA, et al. Among authors: zweegman s. Blood Adv. 2024 Jan 9;8(1):194-206. doi: 10.1182/bloodadvances.2023011658. Blood Adv. 2024. PMID: 38052042 Free PMC article.
Maintain maintenance in multiple myeloma?
Zweegman S, van de Donk NWJC. Zweegman S, et al. Blood. 2023 Nov 2;142(18):1501-1502. doi: 10.1182/blood.2023021781. Blood. 2023. PMID: 37917081 No abstract available.
Treatment sequences and drug costs from diagnosis to death in multiple myeloma.
Seefat MR, Cucchi DGJ, Groen K, Donker ML, van der Hem KG, Westerman M, Gerrits AM, Beeker A, van de Donk NWCJ, Blommestein HM, Zweegman S. Seefat MR, et al. Among authors: zweegman s. Eur J Haematol. 2024 Mar;112(3):360-366. doi: 10.1111/ejh.14119. Epub 2023 Oct 11. Eur J Haematol. 2024. PMID: 37821211
335 results